BioNTech, Pfizer seek FDA authorization of a COVID-19 booster for young children


BioNTech SE BNTX, -2.37% and Pfizer Inc. PFE, +1.45% said Tuesday that they asked the Food and Drug Administration to authorize a COVID-19 booster dose for children between the ages of 5 and 11 years old. Boosters are already authorized for teens and adults. The companies said data from a Phase 2/3 clinical trial yielded no new safety concerns when children in this age group received a booster six months after completing the primary series of shots. So far this year, BioNTech’s stock has tumbled 43.6% and Pfizer shares are down 16.9%, while the S&P 500 SPX, +0.21% has declined 12.4%.

This article was originally published by Read the original article here.

Previous articleCurrencies: Dollar domination continues, as yen slumps to two-decade low
Next articleUnilever turnover and sales rose beat forecasts, despite higher input costs


Please enter your comment!
Please enter your name here